$-0.05
(Market cap
$688 Mln
Recently Viewed
Clear AllMarket cap
$688 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
5.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-201 Mln
ROE
-1.5 %
ROCE
-93.3 %
Industry P/E
--
EV/EBITDA
-3.1
Debt to Equity
1
Book Value
$0.8
EPS
$-1.3
Face value
--
Shares outstanding
180,552,179
CFO
$-338.20 Mln
EBITDA
$-392.50 Mln
Net Profit
$-491.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Prime Medicine
| 12.8 | 11.2 | -16.3 | 131.7 | -33.6 | -- | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Prime Medicine
| 18.8 | -66.7 | -52.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Prime Medicine
|
3.9 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 |
| 3.9 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 | |
| 19.6 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 14.0 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 8.7 | 399.7 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 | |
| 15.5 | 2,154.2 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.7 | |
| 16.9 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 17.9 | 445.5 | 4.8 | 53.5 | -- | 12.2 | 10.8 | 1.2 | |
| 21.7 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic... Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. Read more
President, CEO, Secretary & Director
Dr. Keith Michael Gottesdiener Ph.D.
President, CEO, Secretary & Director
Dr. Keith Michael Gottesdiener M.D., Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Prime Medicine Inc is $3.92 (NASDAQ) as of 23-Apr-2026 10:39 EDT. Prime Medicine Inc has given a return of -33.6% in the last 3 years.
Since, TTM earnings of Prime Medicine Inc is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.57
|
4.28
|
|
2024
|
-1.77
|
2.27
|
|
2023
|
-4.07
|
6.06
|
|
2022
|
-5.19
|
2.00
|
|
2021
|
--
|
--
|
The 52-week high and low of Prime Medicine Inc are Rs 6.94 and Rs 1.11 as of 23-Apr-2026.
Prime Medicine Inc has a market capitalisation of $ 688 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Prime Medicine Inc, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.